Yang L, Xu X, Wang L, Zeng KB, Wang XF. Edaravone administration and its potential association with a new clinical syndrome in cerebral infarction patients: Three case reports. World J Clin Cases 2023; 11(19): 4648-4654 [PMID: 37469729 DOI: 10.12998/wjcc.v11.i19.4648]
Corresponding Author of This Article
Xue-Feng Wang, PhD, Professor, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Jiankang Road, Yuzhong District, Chongqing 400010, China. wangxfyp@vip.163.com
Research Domain of This Article
Clinical Neurology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jul 6, 2023; 11(19): 4648-4654 Published online Jul 6, 2023. doi: 10.12998/wjcc.v11.i19.4648
Edaravone administration and its potential association with a new clinical syndrome in cerebral infarction patients: Three case reports
Liu Yang, Xin Xu, Liang Wang, Ke-Bin Zeng, Xue-Feng Wang
Liu Yang, Department of Neurology, Central Hospital Affiliated to Chongqing University, Chongqing 400010, China
Xin Xu, Liang Wang, Ke-Bin Zeng, Xue-Feng Wang, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
Author contributions: Xu X and Wang XF were responsible for the neurological diagnosis and treatment; Yang L, Wang L, and Zeng KB were major contributors to the writing of the manuscript; All authors have read and approved the final version of the manuscript; Yang L and Xu X are co-authors, they equally contributed to the work.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors have no conflicts of interest to declare.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xue-Feng Wang, PhD, Professor, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Jiankang Road, Yuzhong District, Chongqing 400010, China. wangxfyp@vip.163.com
Received: January 21, 2023 Peer-review started: January 21, 2023 First decision: March 10, 2023 Revised: March 24, 2023 Accepted: June 13, 2023 Article in press: June 13, 2023 Published online: July 6, 2023
Abstract
BACKGROUND
Edaravone is a widely used treatment for patients with cerebral infarction and, in most cases, edaravone-induced side effects are mild. However, edaravone-related adverse reactions have been receiving increasing attention.
CASE SUMMARY
We treated three patients with acute cerebral infarction who died following treatment with edaravone. Edaravone is a widely used treatment for patients with cerebral infarction and, in most cases, edaravone-induced side effects are mild. However, edaravone-related adverse reactions have been receiving increasing attention.
CONCLUSION
Our cases highlight the importance of educating clinicians regarding the new edaravone-induced clinical syndromes of cerebral infarction as potentially fatal adverse drug reactions. Considering that no laboratory or confirmatory test exists to diagnose edaravone-induced death from cerebral infarction, clinicians’ knowledge is the key element in recognizing this phenomenon.
Core Tip: We report three patients with acute cerebral infarction who died after edaravone treatment. Edaravone is used to scavenge oxygen free radicals in patients with acute ischemic stroke, and most clinicians are only aware of its damage to kidney function. However, the main symptoms in patients treated with intravenous edaravone, such as rapid disease change, coagulation dysfunction, cardiac arrest and other side effects are rarely reported. The purpose of this paper is to share the experience of edaravone therapy in clinical practice.
